Baseline demographic and clinical characteristics of patients with amyloidosis and controls fitted with ECGI
| ATTR-CA (n=20) | Controls (n=11) | P value | |
| Age, years (IQR) | 76 (70–79) | 74 (64–78) | 0.528 |
| Male gender, n (%) | 16 (80) | 4 (36) | 0.15 |
| Body mass index, kg/m2 (IQR) | 25 (23–27) | 29 (25–32) | 0.079 |
| NYHA functional class, n (%) | 0.391 | ||
| II | 12 (60) | 6 (55) | |
| III | 8 (40) | 4 (36) | |
| Atrial fibrillation, n (%) | 11 (55) | 7 (64) | 0.641 |
| Hypertension, n (%) | 5 (25) | 5 (47) | 0.244 |
| Pacemaker or ICD, n (%) | 6 (30) | 2 (18) | 0.183 |
| Therapy with beta-blockers, n (%) | 7 (35) | 9 (82) | 0.013 |
| NT-proBNP, pg/mL (IQR) | 3061 (1837–5136) | 948 (468–5586) | 0.113 |
| LVEF, % (IQR) | 51 (41–59) | 59 (51–60) | 0.165 |
| Interventricular septum, mm (IQR) | 22 (19–25) | 13 (12–17) | 0.001 |
Values are given as median and IQR, or total number (n) and %.
ATTR-CA, transthyretin cardiac amyloidosis ; ECGI, electrocardiographic imaging; ICD, intracardiac cardioverter defibrillator; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; NYHA, New York Heart Association.